| Preface | |
| List of Contributors | |
| Structure-Function Studies of the Voltage-Dependent Calcium Channels | p. 1 |
| Regulation of Calcium Channels by Protein Phosphorylation | p. 9 |
| Interactions of Lacidipine and Other Calcium Channel Drugs with Biological Membranes: A Structural Model for Receptor/Drug Binding Utilizing the Membrane Bilayer | p. 15 |
| Regulation of Calcium Channels in Vascular Smooth Muscle | p. 25 |
| Calcium and the Production of Endothelium-Derived Vasoactive Factors | p. 31 |
| Postnatal Development of Calcium Channels in Cardiac Muscle | p. 37 |
| The Hemodynamic Effects of Calcium Antagonists under Pathological Conditions | p. 43 |
| Calcium, Ischemia, and the Calcium Antagonists | p. 49 |
| Multiple Organ Protection through Endothelial Cell Stabilization: A Mechanism of Action of Calcium Antagonists? | p. 59 |
| New Insight into the Vascular Properties of Lacidipine | p. 65 |
| Effect of Felodipine on Left Ventricular Performance in Conscious Dogs: Assessment by Left Ventricular Pressure-Volume Analysis | p. 71 |
| Lacidipine in the Treatment of Hypertension: Clinical Data | p. 77 |
| Insights in the Cardioprotective Mechanism of the New Drug R56865 | p. 87 |
| Do the Differences between Calcium Antagonists Matter when Treating Hypertension? | p. 93 |
| Effects of Lacidipine on Ischemic and Reperfused Myocardium | p. 99 |
| Atherogenic Activity Caused by Excess Membrane Cholesterol in Arterial Smooth Muscle: Role of Calcium Channels | p. 107 |
| Understanding the Initiating Factors in Atherosclerosis: Implications for Intervention | p. 117 |
| Calcium Antagonists and Lipid-Lowering Agents in the Protection of the Arterial Wall | p. 125 |
| Calcium Channel Blockers as Agents for the Treatment of Atherosclerosis | p. 133 |
| Anti-Arteriosclerotic Effects of Calcium Antagonists: Do Calcium Antagonists Inhibit Cholesterol Accumulation in Coronary Arteries of Cholesterol-Fed Rabbits? | p. 139 |
| Cholesterol Enrichment during Dietary Atherosclerosis Alters Smooth Muscle Plasma Membrane Width and Structure: Evidence for Reversal by the 1,4-Dihydropyridine Amlodipine | p. 149 |
| Lacidipine and Atherosclerosis | p. 157 |
| Potentiation of the Antiplatelet Effect of Aspirin by the Calcium Channel Antagonist Amlodipine | p. 165 |
| The Effects of Lacidipine on Insulin Sensitivity | p. 173 |
| Calcium Antagonists, Hypertension, and Atherosclerosis | p. 179 |
| Expression, Localization, and Function of Calcium Channels in NGF-Treated PC12 Cells | p. 183 |
| Receptor-Mediated Inhibition of Calcium Currents and Synaptic Transmission in Cultured Hippocampal Pyramidal Neurons | p. 189 |
| Calcium Stores and Calcium Channels of Cerebellum Purkinje Cells | p. 195 |
| Calcium Channel Signaling in Astrocytes | p. 205 |
| Studies on Synaptosomes: New Insights on Calcium Antagonists | p. 215 |
| The Regulation of Neuronal Calcium Channels | p. 221 |
| Effect of Aging on Brain Voltage-Dependent Calcium Channels | p. 231 |
| Calcium Overload Blockade in Neurons and Cardiomyocytes | p. 241 |
| Effect of Nicardipine on Antioxidant Enzymatic Activities and LTC[subscript 4] Release in Experimental SAH | p. 249 |
| Treatment of Acute Ischemic Stroke with Calcium Antagonists | p. 257 |
| Pharmacological Approach to Acute Ischemic Stroke | p. 265 |
| Calcium Antagonist and Subarachnoid Hemorrhage | p. 271 |
| Pharmacological Basis for Use of Calcium Antagonists in Dementia | p. 279 |
| Calcium Channels in Intestinal Smooth Muscle | p. 285 |
| Pharmacological Aspects of Calcium Channels in Nonvascular Smooth Muscle | p. 291 |
| Pharmacology of Calcium Antagonists Active on Gastrointestinal Calcium Channels | p. 299 |
| Role of Calcium Channels in Pharmacological Modulation of Gastrointestinal Motility | p. 315 |
| A New Class of Calcium Antagonist Selective for the GI Tract | p. 325 |
| Therapeutic Application of Calcium Antagonists in Gastroenterology | p. 337 |
| Calcium Antagonists and the Kidney: Implications for Renal Protection | p. 349 |
| Calcium Antagonists Improve the Outcome after Renal Transplantation | p. 355 |
| Reversal of P-Glycoprotein-Mediated Multidrug Resistance in Tumor Cells by Calcium Channel Antagonists | p. 363 |
| Reversal of Multiple Drug Resistance (MDR) in Malaria by Reverse Isomers of Calcium Channel Blockers and its Possible Application to Cancer and MDR Parasitic Diseases | p. 369 |
| Index | p. 377 |
| Table of Contents provided by Blackwell. All Rights Reserved. |
